Oligomerix, Inc., a privately held company pioneering the development of small molecule therapeutics targeting tau for Alzheimer’s disease (AD) and related neurodegenerative disorders, announces that the company will be presenting at two conferences this month. James Moe, Ph.D., MBA, President and CEO of Oligomerix, will provide a company overview at the 2020 BIO CEO & Investor Conference and present preclinical data on the company’s small molecule inhibitor of tau self-association at the TAU2020 Global Conference.
MORE: https://finance.yahoo.com/news/oligomerix-present-bio-ceo-investor-140000958.html
